Docetaxel-ratiopharm 20mg/ml Konzentrat zur Herstellung einer Infusionslösung clinical trials

A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

This study looks at a new drug, erdafitinib, for people with advanced bladder cancer that has a specific gene change. It compares erdafitinib to standard treatments like pembrolizumab, docetaxel, or vinflunine to see if it helps people live longer.